BioXcel Therapeutics…announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI

Igalmi (dexmedetomedine sublingual) - BioXcel

Jan 20, 2026